Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. - Denlinger CS; Keedy VL; Moyo V; MacBeath G; Shapiro GI (Investigational new drugs, 2021)